ATS Corporation(ATS)Earnings, Financials & Key RatiosATS Corporation (ATS) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q4
while the company achieved 30.1% revenue growth in 2026Q4, the underlying net loss of $16.1 million and high reliance on working capital for liquidity warrant a cautious approach.
ATS Corporation (ATS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
ATS Corporation (ATS) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 28, 2026 | $0.26vs $0.32-18.8% | $535Mvs $529M+1.1% |
| Q1 2026 | Feb 4, 2026 | $0.34vs $0.30+13.3% | $554Mvs $526M+5.3% |
| Q4 2025 | Nov 5, 2025 | $0.33vs $0.31+6.5% | $523Mvs $733M-28.6% |
| Q3 2025 | Aug 7, 2025 | $0.30vs $0.27+11.1% | $541Mvs $718M-24.7% |
Recent stock market news and headlines for ATS Corporation (ATS)
[url="]Interactive Brokers[/url] (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea
ATS, BXBLY and SKY have been added to the Zacks Rank #5 (Strong Sell) List on June 29, 2026.
Investors need to pay close attention to ATS stock based on the movements in the options market lately.
NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) -- Fusemachines Inc. (NASDAQ: FUSE), a leading provider of enterprise AI products and services, today announced expanded enterprise access to its Agentic AI for Talent Acquisition platform through new connectivity with more than 30 enterprise applicant tracking systems (ATS), enabling Fusemachines Agents to work directly within the systems organizations already use to manage talent and hiring. This expanded connectivity represents the first in a broader series of planned platform enhancements designed to bring AI-powered recruiting capabilities closer to the workflows, data, and systems recruiters rely on every day.
Not intended for UK and US audiences Nerandomilast long-term survival modeling presented at American Thoracic Society (ATS) 2026 and European Alliance of Associations for Rheumatology (EULAR) 2026 international congresses. Based on the modeling, nerandomilast consistently increased median survival in both idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).1,2 Modeling predicts meaningful extensions in survival with nerandomilast, including a multi-year increase in median survival when used as monotherapy, and additional gains when added to standard treatment.1,2 Ingelheim, Germany - Long-term survival modeling of Boehringer Ingelheim's oral preferential PDE4B inhibitor, nerandomilast, predicts the therapy could extend survival by up to 5.4 years in adults with idiopathic pulmonary fibrosis (IPF) and up to 3.3 years in adults with progressive pulmonary fibrosis (PPF), compared with no therapy.1,2 These findings are based on data from the Phase III FIBRONEER™ trials and were recently presented at the ATS and EULAR 2026 international congresses.
Key metrics vs top competitors for ATS Corporation (ATS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $27.57 | $2.7B | 53.68 | 17.35% | 2.41% | 4.11% | — | |
| $363.76 | $37.44B | 25.62 | 12.26% | 21.12% | 8.75% | — | |
| $84.44 | $3.74B | 12.97 | -3.02% | 12.32% | 17.22% | — | |
| $147.85 | $5.27B | 100.58 | 3.3% | 5.35% | 5.08% | — | |
| $349.57 | $23.53B | 79.99 | 9.62% | 8.03% | 12.24% | — | |
| $53.73 | $12.73B | 30.70 | -2.61% | 12.37% | 7.95% | — |
ATS Corporation (ATS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when ATS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ATS Corporation (ATS) stock FAQ — growth, dividends, profitability & financials explained
ATS Corporation (ATS) reported $2.97B in revenue for fiscal year 2026. This represents a 1090% increase from $249.8M in 1997.
ATS Corporation (ATS) grew revenue by 17.4% over the past year. This is strong growth.
Yes, ATS Corporation (ATS) is profitable, generating $71.6M in net income for fiscal year 2026 (2.4% net margin).
ATS Corporation (ATS) has a return on equity (ROE) of 4.1%. This is below average, suggesting room for improvement.
ATS Corporation (ATS) generated $392.2M in free cash flow for fiscal year 2026. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
